Valuation: Sanofi

Market Cap 90.49B 104B 84.71B 77.3B 145B 9,959B 148B 993B 389B 4,985B 392B 384B 16,631B P/E 2026 *
12x
P/E 2027 * 10.5x
Enterprise Value 102B 118B 95.4B 87.05B 164B 11,216B 167B 1,119B 438B 5,614B 442B 432B 18,729B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.95x
Free-Float
88.34%
Yield 2026 *
5.63%
Yield 2027 * 5.96%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-8.92%-.--% - - 105B
-0.75%+9.71%+92.69%+131.70% 1,098B
-0.69%+1.80%+49.31%+49.28% 631B
+0.89%+2.21%+25.45%+63.75% 438B
-1.13%+3.13%+49.78%+39.13% 368B
-0.74%+1.01%+31.08%+38.64% 298B
-1.22%+0.89%+7.32%+7.38% 251B
-0.67%+6.27%+45.38%+57.88% 226B
+0.34%-0.13%-4.77%-50.50% 209B
+2.49%+0.83%+13.20%+70.46% 165B
Average -0.99%+1,657.21%+34.38%+45.30% 409.37B
Weighted average by Cap. -0.60%+1,331.50%+50.18%+66.64%

Financials

2026 *2027 *
Net sales 47.51B 54.82B 44.47B 40.58B 76.36B 5,229B 77.65B 521B 204B 2,617B 206B 201B 8,731B 50.61B 58.4B 47.38B 43.23B 81.35B 5,570B 82.72B 556B 218B 2,788B 219B 214B 9,301B
Net income 7.94B 9.16B 7.43B 6.78B 12.76B 874B 12.98B 87.17B 34.15B 437B 34.41B 33.66B 1,459B 9.27B 10.69B 8.68B 7.92B 14.9B 1,020B 15.15B 102B 39.86B 511B 40.15B 39.28B 1,703B
Net Debt 11.42B 13.17B 10.69B 9.75B 18.35B 1,256B 18.66B 125B 49.09B 629B 49.46B 48.38B 2,098B 8.23B 9.5B 7.71B 7.03B 13.23B 906B 13.46B 90.37B 35.41B 454B 35.67B 34.89B 1,513B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
75.53EUR
Average target price
94.28EUR
Spread / Average Target
+24.82%

Quarterly revenue - Rate of surprise